Multiple cytokines are secreted by Hodgkin lymphoma (HL) cells, notably interleukin-6 (IL6), which is believed to play a significant pathobiological role in this and certain other tumors. Previous work on prostate carcinoma cells has shown that IL6 expression is activated therein by the homeodomain protein GBX2, which we found to be absent in HL cells. Instead, we observed expression of a closely related gene, HLXB9, albeit restricted to HL cells coexpressing IL6. Treatment of HL cell lines with antisense-oligonucleotides directed against HLXB9, forced expression of recombinant HLXB9, and analysis of reporter gene constructs containing IL6 promoter sequences all confirmed the potential of HLXB9 to drive expression of IL6. Chromosomal rearrangements of the HLXB9 locus at 7q36 were not detected in HL cells unlike AML subsets expressing HLXB9. However, inhibition of certain signal transduction pathways revealed that the phosphatidylinositol 3 kinase (PI3K) pathway contributes to HLXB9 expression. AKT/phospho-AKT analysis revealed constitutively active PI3K signalling in HL cell lines. Downstream analysis of PI3K revealed that E2F3 may mediate activation of HLXB9. Taken together, our data show that the PI3K signalling pathway in HL cells is constitutively activated and promotes HLXB9 expression, probably via E2F3, thereby enhancing malignant expression of IL6.
Introduction
Hodgkin lymphoma (HL) is a lymphoid malignancy characterized by the presence of rare neoplastic Hodgkin/Reed-Sternberg (H/RS) cells within infiltrated lymph nodes, which become enriched with reactive lymphocytes, hindering analysis of HL at the molecular level. Therefore, authentic and well characterized HL cell lines that share many features with H/RS cells are effective investigational tools. 1 HL cells express multiple cytokines, notably interleukin-6 (IL6), which contributes to the immunoreactive phenotype and of which high levels are associated with bad prognosis. [2] [3] [4] Both transcription factors NFkB 5 and AP-1 6 are constitutively activated in HL cells driving expression of IL6, [7] [8] [9] [10] and also disturbing the pro/antiapoptotic balance. 11 Additional constitutive activities reported in HL cells include the Janus kinase/signal transducer and activator of transcription (JAK/STAT) 12 and mitogen-activated protein kinase (MAPK) 13 signal transduction pathways, and deregulated expression of CCNE1, 14 polycomb proteins EZH2 15, 16 as well as RYBP. 17 Homeobox genes code for transcription factors, occupying central roles in development and differentiation. Their classification reflects sequence similarities within the 'homeobox' coding for the 'homeodomain' responsible for sequence specific DNA binding. 18 Dysregulated homeobox genes are key players in neoplasia, 19, 20 their tumorigenic properties apparently related to structural motifs and therefore marked within certain gene families. Thus, the NKX homeobox gene family comprises 14 members, three of which, TLX1, TLX3, and NKX2-5, are known to be involved in T-cell acute lymphoblastic leukemia, relating structural with oncogenic properties. [21] [22] [23] In contrast to other lymphoid neoplasms, reports detailing the widespread involvement of homeobox genes in HL have been hitherto largely restricted to the attenuation therein of the B-cell commitment program orchestrated by PAX5.
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This study addresses the role of an EHG homeobox gene family member, HLXB9, 21 as an activator of IL6 in HL cells. HLXB9 is normally expressed in neuronal 25 and pancreatic cells 26 and mutated in the Currarino syndrome combining anorectal malformations with sacral agenesis. 27 Ectopic expression of HLXB9 may be induced by chromosomal rearrangements in acute myeloid leukemia (AML). 28, 29 In this study we have identified a constitutively active phosphatidylinositol 3 kinase (PI3K) pathway underlying HLXB9 expression, probably mediated by E2F3 which also leads to activation of CCNE1.
Materials and methods

Cell lines and culture
Cell lines used in this study are all reposited with the DSMZ (Braunschweig, Germany). Details of origin, pathobiological properties, and cell culture conditions are given by Drexler.
1 For gene stimulation we used 12-O-tetradecanoylphorbol-13-acetate (TPA), obtained from Genzyme (Rü sselsheim, Germany) and dissolved in dimethylsulfoxide (DMSO). For antisense experiments, cells were treated for 3 days with 5 mM (replenished daily) phosphorothioate-modified antisense-oligonucleotides (MWG Biotech, Ebersberg, Germany). Sequences of antisense-oligonucleotides are listed in Supplementary Table 1 (http://www.nature.com/leu). Inhibition of secreted IL6 protein was performed using anti-IL6 antibody (R&D Systems, Wiesbaden, Germany) and for stimulation experiments IL6 protein was purchased from Strathmann Biotec AG (Hamburg, Germany). For analysis of signal transduction pathways, the following pharmacological inhibitors were used: AG490 (Biomol/Upstate Biotechnology, Hamburg, Germany), PD98059 (Sigma, Taufkirchen, Germany), rapamycin (ICN Biomedicals, Meckenheim, Germany), and wortmannin (Sigma). L-540 cells were transfected with 2 mg DNA by electroporation using EPI 2500 (Fischer, Heidelberg, Germany) with 350 V for 10 ms. Adherent cell lines were transfected with 2 mg DNA using Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany).
Reverse transcription (RT)-PCR analysis
RNA extraction and cDNA synthesis, amplification and analysis of the PCR products were performed as described previously. 22 Sequences of primers used for PCR are listed in Supplementary Table 1 (http://www.nature.com/leu). Quantitative real-time RT-PCR was performed as described previously. 30 
Protein analysis
Quantification of IL6 protein within the culture medium supernatant without any cells was performed by ELISA using the Quantikine Human IL-6 Immunoassay (R&D Systems). The OD values were measured by an automated ELISA reader (Titertek Multiscan, MCC/340; Flow ICN, Meckenheim, Germany). Protein detection by Western blot was performed as described previously. 22 The following antibodies were used: anti-Hb9/ HLXB9 (Chemicon, Temecula, CA, USA), anti-AKT, anti-phospho AKT, anti-E2F3 (Santa Cruz, Santa Cruz, CA, USA), anti-S6, and anti-phospho S6 (Cell Signaling, Beverly, MA, USA). 
DNA cloning and sequencing
Flow cytometry
Apoptotic cells were detected and quantified with the annexin-V/ propidium iodide (PI) method, applying a commercially available kit (R&D Systems), and determined by flow cytometry. For cell cycle analysis, DNA content was determined by flow cytometry on the FACScan (Becton Dickinson, Heidelberg, Germany).
Fluorescence in situ hybridization (FISH)
FISH was performed as described previously. 
Results and discussion
Regulation of IL6 expression in HL cell lines
To investigate regulation of IL6 in HL cells we first determined its expression in six well-characterized HL cell lines by both RT-PCR ( Figure 1 , Supplementary Table 2) and ELISA ( Table 1 ). The signal intensities of PCR products were consistent with IL6 protein amounts quantified by ELISA. The strongest expression was observed in HDLM-2 and L-1236, with lower levels in KM-H2, L-428, and SUP-HD1, while no significant expression was detected in L-540. 12 Both NFkB and AP-1 are constitutively active in most HL cells 5, 6 or inducible by TPA in the remainder. 31 Thus, TPA treatment of KM-H2 with low levels of constitutive AP-1 activity, 6 and of L-540, which lacks constitutive NFkB activity, 31 respectively, elevated or induced expression of IL6 therein (Table 1) . These results confirm that expression of IL6 depends on AP-1 and NFkB activation in the HL cell lines used in this study.
The homeodomain protein GBX2 activates IL6 expression in prostate carcinoma cells 32 and IL6-related growth factor cMGF 33 in avian AML cells. 34 GBX2 is a member of the EHG family of homeobox genes comprising EN1, EN2, HLXB9, GBX1, and GBX2. 21 We screened expression of all five genes by RT-PCR in HL cell lines (Figure 1, Supplementary Table 2) . In contrast to PC-3 (prostate carcinoma) cells, no HL cell line expressed GBX2, while HLXB9 was expressed in all HL cell lines excepting L-540, faithfully reflecting IL6 expression (Supplementary Table 2 ). We postulated, therefore, that HLXB9 might play a role in activating IL6 expression in HL cells akin to GBX2 in prostate carcinoma cells. However, Western blot 
AS-HLXB9 403713
IL6 protein was measured in 1 ml medium of 1 Â 10 6 cells produced after 24 h. Cells were treated with 1 Â 10 À7 M TPA dissolved in DMSO or with 5 mM antisense-oligos.
HLXB9 in Hodgkin's lymphoma cell lines
S Nagel et al analysis of HLXB9 protein expression revealed very low levels when compared to the AML cell line GDM-1, where expression is upregulated by juxtaposition with MYB via a chromosomal rearrangement, t(6;7)(q23;q36). 29 KM-H2 was the only HL cell line with detectable HLXB9 protein (Figure 2 ), consistent with its predominant RT-PCR signal (Figure 1) . Thus, HL cells translate only moderate-to-low levels of HLXB9.
To investigate whether HLXB9 activates IL6 in HL cell lines, we performed series of experiments designed to modulate expression of endogenous HLXB9 and to dissect the role of HLXB9 binding to IL6 promoter sequences. For overexpression experiments we cloned full-length HLXB9 cDNA into an expression vector (pcDNA3) generating pcrHLXB9 (Figure 3a) . L-540 cells were transfected by electroporation (efficiency o10%). RT-PCR analysis showed enhancement of IL6 expression exclusively in combination with TPA stimulation, indicating a coactivatory role for HLXB9 (Figure 3b ). For knockdown of HLXB9 expression we used an antisense-oligonucleotide (AS-HLXB9) previously shown to reduce both HLXB9 RNA and protein. 29 Treatment with AS-HLXB9 reduced both HLXB9 and IL6 RNA expression in HDLM-2 cells (Figure 3c ) and IL6 protein expression in L-428 cells (Table 1) , showing clearly the dependence of IL6 expression on HLXB9.
For promoter studies we cloned IL6 promoter sequences before a reporter gene, enhanced green fluorescence protein (EGFP) (Figure 4) . The largest promoter construct (pIL6.1-EGFP) contained putative binding sites for AP-1, NFkB, and GBX2/ HLXB9. The DNA-binding sequence of HLXB9 matched that described for GBX2. 32 Table 2 ). In contrast to 293 cells (no green cells visible), HeLa and PC-3 yielded about 30% greenpositivity, reflecting the transfection efficiency of pEGFP-N1 detected microscopically. Treatment of pIL6.1-EGFP transfected HeLa cells with AS-HLXB9 reduced positivity to 20% ( Table 2) . Analysis of HeLa cells transfected with IL6 deletion construct lacking the GBX2/HLXB9 binding site (pIL6.2-EGFP) reduced positivity to 23% ( Table 2 ). Deletion of additional 200 bp (pIL6.3-EGFP) showed no further reduction (22%). In contrast, pIL-6.4-EGFP lacking both AP-1 and NFkB binding sites yielded scarcely any green cells (Table 2 ). Flow cytometric analysis of HeLa cells transfected with IL6 deletion constructs revealed similar data (Table 2) . Taken together, these results demonstrate 
Figure 4
Schematic diagram of IL6 promoter constructs. IL6 promoter sequences were cloned before a reporter gene (EGFP). Potential binding sites for AP-1, NFkB, and GBX2/HLXB9 (EHG) are indicated. Cell lines were transfected with IL6 promoter constructs comprising reporter gene enhanced green fluorescence protein (EGFP) as shown in Figure 4 . After 24 h, green fluorescent cells were counted by fluorescence microscopy or FACS (mean of intensity).
HLXB9 in Hodgkin's lymphoma cell lines S Nagel et al a direct positive role for promoter binding of HLXB9 on the regulation of IL6 expression. MCL1 is a BCL2-like antiapoptotic gene and a potential downstream target of IL6, which is highly expressed in HL cells. 36, 37 Treatment of HDLM-2 cells with antisense-oligo directed against IL6 (AS-IL6) or with inhibitory anti-IL6 antibody reduced expression of MCL1 as analyzed by RT-PCR (Supplementary Figure 1a ). An AS-HLXB9 treatment of HDLM-2 and KM-H2 cells reduced cell viability, which could, however, be rescued by simultaneous treatment with exogenous IL6 (Supplementary Figure 1b) , demonstrating a functional relation between these genes. Treatment of L-1236 cells with AS-HLXB9, AS-IL6, and AS-MCL1 showed a reduction of viable cells in the absence of FBS (Supplementary Figure 1c) . This implies an antiapoptotic role for IL6 in HL cells consistent with previous data concerning IL6 in this context. 12 L-540 cells express MCL1, though lacking both NFkB activity 31 and HLXB9 expression (Figure 1 , Supplementary Table 2 ). However, L-540 exhibits very strong constitutive STAT3 activity, 12 which may substitute the active autocrine IL6 signalling pathways present in the other HL cell lines. Taken together, our data suggest that HLXB9 directly enhances expression of IL6 in HL cell lines. It is likely that expression of IL6 mediates an antiapoptotic effect via activation of MCL1.
Activation of HLXB9 in HL cell lines
Recently, we showed the HLXB9 locus (at 7q36) to be activated by chromosomal juxtaposition with MYB (at 6q23) via t(6;7)(q23;q35) in GDM-1 cells derived from AML. 29 Other types of chromosome rearrangement involving HLXB9 have also been reported. 28 In contrast, conventional and FISH analyses confirmed the absence of chromosome rearrangements of HLXB9 in all of the HL cell lines in this study (data not shown). In avian AML, GBX2 may be activated by mutated MYB alone, or in combination with activated signal transduction pathways, if wild type. Consideration of these findings prompted investigation whether an analogous mechanism might be responsible for HLXB9 expression in HL cells. Expression of MYB was confirmed by Western blot analysis in HL cell lines, 29 although HDLM-2 expresses low levels only (see below). No mutations were detected within the DNA binding domain of MYB in HDLM-2, L-1236, or L-428 (data not shown). Neither the expression of normal MYB by L-540 cells (HLXB9-negative) nor the failure of AS-MYB treatment of KM-H2 cells to reduce HLXB9 expression therein (data not shown) support the direct influence of MYB on HLXB9 expression in HL cells.
The contribution of known signal transduction pathway activity to HLXB9 activation was assessed by treating L-1236 cells with the following specific pathway inhibitors: wortmannin (PI3K pathway), AG490 (JAK/STAT pathway), and PD98059 (MAPK pathway). Reduced HLXB9 expression was detected by RT-PCR 1 day after treatment with wortmannin and AG490, verified quantitatively by real-time PCR (Figure 5a ). JAK/STAT and MAPK pathways have been shown to be constitutively active in HL cell lines. 12, 13 To see if the same is valid for the PI3K pathway, we performed AKT/phospho-AKT Western blot analysis. Excepting HDLM-2, all HL cell lines express phosphorylated AKT, indicating constitutive activity of this pathway (Figure 2) . HLXB9 expression resisted all attempts at pathway inhibition in HDLM-2 cells (Figure 5b) . Inhibition of the JAK/ STAT pathway in HDLM-2 had no effect on HLXB9 expression despite constitutive activity 12 prompting further investigation of the PI3K pathway.
Phospho-AKT, without downstream targeting of GSK3beta and beta-catenin has been detected in lymph nodes of HL patients. 38 Here, we analyzed another branch of the PI3K pathway. Rapamycin inhibits mTORkinase also located downstream of PI3K. 39 RT-PCR analysis of HLXB9 after rapamycin treatment showed reduction of PCR signals in L-428 and SUP-HD1, but not in HDLM-2, demonstrating the effect of this branch of the PI3K pathway in HLXB9 expression (Figure 6a ). MYB is a known downstream target of PI3K 40 and its underexpression in HDLM-2 cells 29 is consistent with the absence of PI3K activity in this cell line. p70S6kinase, acting downstream of mTORkinase, phosphorylates ribosomal protein S6. Strong S6 phosphorylation is visible in KM-H2, L-1236, L-428, and SUP-HD1, but neither in HDLM-2 nor in L-540 (Figure 2 ), indicating that in L-540 the PI3K pathway is interrupted between PI3K and p70S6kinase and probably unable, therefore, to mediate activation of HLXB9.
To investigate deregulation of HLXB9 in HDLM-2 cells (devoid of PI3K activity), we measured expression of downstream factors described in other contexts. In mouse neurons transcription factors, SP-1 and E2F activate HLXB9 promoter constructs lacking upstream tissue-specific enhancers, albeit weakly. 35 Analysis of SP-1, E2F1, E2F2, and E2F3 (Figure 1 , Supplementary Table 2) by RT-PCR revealed overexpression of E2F3 in HDLM-2 and to a lesser extent in KM-H2. Overexpression of E2F3 via genomic amplification was shown recently in 5637 compared to T-24 urinary bladder carcinoma cells. 41 Comparative RT-PCR and Western blot analyses in HDLM-2 and bladder carcinoma cells (Figure 6b ), and HL cell lines (Figure 2) , respectively, confirmed overexpression of E2F3 in HDLM-2. However, FISH analysis of the E2F3 locus in HL cell lines revealed no rearrangements (data not shown). Since E2F factors are inhibited by Rb, itself regulated by the PI3K pathway, [42] [43] [44] we decided to investigate deregulation of HLXB9 by E2F3 in HL cells. Two splice variants (A and B) have been described for E2F3, 45 both expressed in HL cell lines (Supplementary Table 2 ). Treatment of L-1236 cells with AS-E2F3A markedly reduced expression of HLXB9 (Figure 6c ). Other known targets of E2F transcription factors 46 overexpressed in HL include CCNE1 and EZH2.
47,48 CCNE1 expression was also downregulated after antisense treatment by AS-E2F3A (Figure 6c ), confirming the significance of this factor. HeLa cells express HLXB9 at the G1-S phase transition, 49 which is known to be regulated by Rb and E2F3 factors. 50 L-1236 cells treated with wortmannin for 48 h clearly showed a G1 cell cycle arrest (data not shown), demonstrating a proliferative role for the PI3K pathway in HL cells and confirming the potential activation of E2F3. Taken together, these results indicate that E2F3 drives HLXB9 expression in HL cells, and that a variety of mechanisms including PI3K signalling may be involved.
Recently, E2F2 and E2F3 were shown to bind the polycomb protein YY1 via another polycomb protein, RYBP, which is known to be overexpressed in HL cells. 17, 51, 52 We observed both YY1 and RYBP expression in HL cell lines (Figure 1 ), while analysis of HLXB9 promoter sequence revealed binding sites for both E2F factors and YY1 near the transcriptional start point. This may suggest that deregulated expression of both E2F3 and RYBP underlie activation of HLXB9.
Conclusion
We have shown that HLXB9 is expressed by HL cells where it regulates IL6, thus placing HLXB9 alongside two other known IL6 regulators, AP-1 and NFkB. We have also shown that activation of HLXB9 in HL cells is responsive to constitutive PI3K signalling probably via E2F3 in concert with YY1 and RYBP. Thus, IL6 dysregulation in HL cells parallels that in prostate carcinoma involving another closely related homeodomain protein GBX2. Our data imply that EHG homeobox gene family members may be more generally involved in neoplastic IL6 activation. PI3K signalling contributes to tumorigenesis among many cancers and our data suggest its pathologic role in HL also deserves wider investigation. 
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